Fig. 2.

Treatment with mature dendritic cells (DCm) loaded with GL261 RNA (DCm-GL261-RNA) results in a GL261-tumor–specific immune response in vivo. To address specificity in vivo, mice were either left untreated or prophylactically treated with DCm-GL261-RNA or DCm loaded with MC17-51 RNA and subsequently subcutaneously (SC) challenged with GL261 glioma (●) or MC17-51 fibrosarcoma (○) cells. The growth of SC tumors was measured with a caliper. For each group, the onset (in days after tumor challenge) of a detectable tumor mass is depicted.